Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 6/20 | 0.51 |
| ▸ | RECQL | P46063 | 1/20 | 0.50 |
| ▸ | FPR2 | P25090 | 2/20 | 0.49 |
| ▸ | PROKR1 | Q8TCW9 | 2/20 | 0.49 |
| ▸ | PDE4B | Q07343 | 6/20 | 0.49 |
| ▸ | PDE4D | Q08499 | 5/20 | 0.48 |
| ▸ | PDE4C | Q08493 | 3/20 | 0.48 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.47 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5369483 | 0.85 | HTR2C (0.58) | SLC6A4 | |
| SCHEMBL8209414 | 0.81 | PDE4A (0.67) | PDE4AFPR2PDE4BPDE4DPDE4C | |
| SCHEMBL2907378 | 0.81 | ACHE (0.59) | PDE4ARECQLPDE4BPDE4DPDE4C | |
| SCHEMBL21243673 | 0.81 | HTR2C (0.47) | PDE4BPDE4DSLC6A4CSNK2A1 | |
| SCHEMBL2287648 | 0.80 | SLC6A4 (0.68) | SLC6A4 | |
| SCHEMBL2908060 | 0.79 | PDE4A (0.51) | PDE4ARECQLPDE4BPDE4DPDE4C | |
| SCHEMBL10196687 | 0.79 | ACHE (0.57) | PDE4ARECQLPDE4BPDE4DPDE4C | |
| SCHEMBL3457608 | 0.79 | PDE4A (0.51) | PDE4ARECQLPDE4BPDE4DPDE4C | |
| SCHEMBL14244189 | 0.79 | RECQL (0.60) | PDE4ARECQLPDE4BPDE4DPDE4C | |
| SCHEMBL8478398 | 0.78 | PDE4A (0.58) | PDE4APDE4BPDE4DPDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1692109-B1 | PHOSPHODIESTERASE 4 INHIBITORS, INCLUDING N-SUBSTITUTED DIARYLAMINE ANALOGS | MEMORY PHARM CORP (US) | 2010-08-18 | — | — | EP | disclosed |
| US-20050222207-A1 | Phosphodiesterase 4 inhibitors, including N-substituted diarylamine analogs | MEMORY PHARMACEUTICAL CORPORATION | 2005-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050222207-A1 | Phosphodiesterase 4 inhibitors, including N-substituted diarylamine analogs | PDE4A, PDE4B, PDE3B | PDE4A 1/4885RECQL 137/4885FPR2 3972/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.